首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TNFSF1 |
| Uniprot No | P01374 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 35-205aa |
| 氨基酸序列 | LPGVGLTPSAAQTARQHPKMHLAHSTLKPAAHLIGDPSKQNSLLWRANTDRAFLQDGFSLSNNSLLVPTSGIYFVYSQVVFSGKAYSPKATSSPLYLAHEVQLFSSQYPFHVPLLSSQKMVYPGLQEPWLHSMYHGAAFQLTQGDQLSTHTDGIPHLVLSPSTVFFGAFAL |
| 预测分子量 | 20.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TNFSF1(TNF-α)重组蛋白的3篇代表性文献概览：
1. **"Crystal structure of the human TNF-α in complex with its receptor"**
**作者**: Banner, D.W. 等
**摘要**: 该研究解析了人源重组TNF-α与其受体结合的晶体结构，揭示了TNF-α三聚体如何通过特定区域激活下游信号通路，为靶向TNF的药物治疗炎症性疾病提供了结构基础。
2. **"Production of biologically active recombinant human TNF-α in E. coli"**
**作者**: Marmenout, A. 等
**摘要**: 报道了通过大肠杆菌表达系统高效生产具有生物活性的重组人TNF-α蛋白的方法，验证了其体外诱导肿瘤细胞凋亡和激活免疫细胞的功能，为大规模生产奠定基础。
3. **"TNFSF1 regulates T cell responses through epigenetic remodeling of cytokine genes"**
**作者**: Li, Y. 等
**摘要**: 发现重组TNFSF1蛋白可通过调控T细胞表观遗传修饰(如组蛋白乙酰化)，影响IL-2和IFN-γ等细胞因子的表达，揭示其在免疫调节中的新机制。
注：若需具体文献年份或期刊，可进一步补充检索。实际引用时建议通过PubMed等平台核对最新研究进展。
Tumor necrosis factor superfamily member 1 (TNFSF1), also known as lymphotoxin-alpha (LT-α), is a cytokine belonging to the TNF superfamily, first identified in the 1960s for its antitumor activity. It exists in both soluble homotrimeric (LT-α3) and membrane-bound heterotrimeric (LT-α1β2) forms, interacting with receptors such as TNFRSF1A, TNFRSF1B, and HVEM to regulate immune responses. TNFSF1 is primarily produced by activated lymphocytes and plays critical roles in lymphoid organ development, immune cell communication, and inflammatory responses. It activates NF-κB and MAPK signaling pathways, influencing processes like apoptosis, cell proliferation, and pathogen defense. Dysregulation of TNFSF1 is linked to autoimmune diseases (e.g., rheumatoid arthritis), chronic inflammation, and cancer.
Recombinant TNFSF1 protein is engineered using expression systems (e.g., E. coli, mammalian cells) to produce bioactive forms for research and therapeutic applications. It retains functional epitopes, enabling studies on receptor interactions, signaling mechanisms, and immune modulation. In drug development, TNFSF1 serves as a tool for screening inhibitors or agonists targeting TNF-related pathways. Its therapeutic potential is explored in cancer immunotherapy and autoimmune disorders, though challenges include managing systemic toxicity and optimizing delivery. As a research reagent, recombinant TNFSF1 aids in elucidating its dual role in promoting inflammation and maintaining immune homeostasis, offering insights into disease mechanisms and targeted interventions.
×
